NUCALA achieved and maintained normal eosinophil levels

The reduction in blood eosinophils seen at Week 4 in the NUCALA group was maintained through Week 521

Reduction in blood eosinophils seen at week 4 graph
Reduction in blood eosinophils seen at week 4 graph
Lungs Icon


eosinophil reduction

at Week 52 vs placebo*

NUCALA mean blood eosinophil levels:

  • 177 cells/µL at baseline
  • 38 cells/µL at Week 52

Results are descriptive. The clinical significance of these pharmacodynamics data is unknown.

Placebo, 216 cells/µL at Week 52 (172 cells/µL at baseline). Counts given as geometric mean.1

Note: Mean normal blood eosinophil levels in a general population of subjects without confounding factors have been reported as 100 cells/µL (range: 34-257) and 107 cells/µL (5th, 95th percentile: 30, 395); levels vary based on age, sex, environmental exposures, and comorbid conditions.2,3

NUCALA: The first and ONLY anti-IL-5 for eosinophilic granulomatosis with polyangiitis (EGPA)

NUCALA targets interleukin-5 (IL-5), the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils.




The mechanism of action of mepolizumab in EGPA has not been definitively established.

Role of eosinophils in health and EGPA

Permanent J-code for NUCALA


Role of eosinophils in health image
Role of eosinophils in health image

The role of eosinophils in maintaining health includes4:

  • Regulating the immune system
  • Tissue regeneration and repair
  • Host protection (eg, defending against parasitic infection)

In EGPA, eosinophilia leads to5:

  • Inflammation
  • Tissue/organ damage